Directcare offers independently validated testing by CLIA-certified labs in compliance with FDA notification guidelines under the 2020 Emergency Use Authorization Act. We strive for quality, convenience and fast results. Our partner labs currently offer serology antibody testing and PCR Swab testing requiring a physician lab order which is included in our pricing.
Directcare is led by a cadre of medical professionals including esteemed Cedars-Sinai physician Benjamin Basseri, MD who serves as Medical advisor and director. We've assembled a team of certified allied medical providers who are passionate about delivering top tier concierge service at every appointment.
Our mission is to make healthcare convenient by delivering reliable services directly to your home.
Which tests are offered through our partner labs?
Covid-19 Laboratory Developed PCR Test
Covid-19 virus is known scientifically as SARS-CoV-2. Primex, Roche, Thermo Fisher, Ortho Clinical are listed on the FDA Emergency Use Authorization at the FDA website, under FAQs on Diagnostic Testing for SARS-CoV-2.
All swab tests have high sensitivity and high specificity.
Sensitivity - The Primex LDT assay reads the viral copies to 250 copies/mL.
Specificity - The Primex LDT assay reported “Not Detected” on samples with known positives for associated viral pathogens, but reported “Detected” on known positive samples for SARS-CoV-2.
SARS-CoV-2 (COVID-19) Antibody, IgG and IgM Tests
Primex is performing the SARS-CoV-2 Antibody, IgG and IgM Tests in combination. Below is some background information on this testing.
After infection with SARS-CoV-2, viral antigens stimulate the body’s immune system to produce antibodies. The virus incubation period and the days/weeks when the antibodies appear in the blood are defined below.
SARS-CoV-2 virus Antibodies, IgM and IgG
- IgM appears early in the blood circulation after an infection (as early as 3-5 days).
- IgG appears later in the blood circulation after an infection (within 3-4 weeks).
The medical device manufacturer for the SARS-CoV-2 IgM and IgG CLIA Kits that Primex is evaluating provides the following information:
"The IgM and IgG tests are able to detect the antibodies to the SARS-CoV-2 virus and the kits have high specificity, sensitivity and clinical agreement with samples confirmed with PCR methods (RT-qPCR)".
Sensitivity with the SARS-CoV-2 IgM and IgG CLIA Kits
- IgM - When ordered with the IgG test, sensitivity was 89.9%.
- IgG - When ordered with the IgM test, sensitivity was 95.6%.
Specificity with the SARS-CoV-2 IgM and IgG CLIA Kits
- IgM - When ordered with the IgG test, specificity was 96.5%.
- IgG - When ordered with the IgM test, specificity was 96.0%.
The kit manufacturers are also listed on the FDA’s EUA website under FAQs on Diagnostic Testing for SARS-CoV-2.
Incubation Period for Covid-19 virus
- Median Incubation period: 5.1 days (95% confidence interval, 4.5 to 5.8 days)
- 97.5 % of those who develop symptoms do so within 11.5 days (CI 8.2 to 15.6 days)
Ortho Clinical Antibody Test
“Ortho is proud that both of our COVID-19 total and IgG tests are achieving 100% specificity,” said Chris Smith, Ortho Clinical Diagnostics’ Chief Executive Officer. “During this health crisis, good is simply not good enough. This high level of specificity is a testament to Ortho’s strong belief that every test is a life.”
Ortho’s COVID-19 IgG antibody test detects the IgG antibody. It closely follows the introduction of Ortho’s COVID-19 Total test and the two tests offer greater choice in tracking and surveillance, patient management, and screening convalescent plasma. Both of Ortho’s tests help health care professionals understand if a patient has been exposed to and has developed antibodies to the SARS-CoV-2 virus.
Ortho’s COVID-19 IgG antibody test received Emergency Use Authorization from the U.S. Food and Drug FDA administration on April 24, 2020. Ortho’s total antibody test received CE Mark on May 8, 2020 and FDA Emergency Use Authorization on April 14, 2020.
Benjamin Basseri, MD
A Los Angeles native, Dr. Basseri graduated Summa Cum Laude with Honors at UCLA, where he earned a Bachelor of Science degree in Neuroscience. Dr. Basseri then attended the UCLA Geffen School of Medicine where he received multiple Letters of Distinction, including in GI Medicine and Hepatology. He completed his residency in Internal Medicine at Cedars-Sinai Medical Center.